What are the most common mistakes with Octreotide (Sandostatin)?
The most common Octreotide (Sandostatin) mistakes are treating it as a body-comp peptide (it's a hormone suppressor for medical indications); skipping the gallbladder monitoring on long term use; not anticipating the hyperglycemic effect. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for Octreotide (Sandostatin) is limited.
Common Octreotide (Sandostatin) mistakes
- Treating it as a body-comp peptide (it's a hormone suppressor for medical indications)
- Skipping the gallbladder monitoring on long term use
- Not anticipating the hyperglycemic effect
Bloodwork worth tracking
- IGF-1 (target of therapy)
- Fasting glucose
- Vitamin B12 yearly
- Gallbladder ultrasound periodically
References
- Octreotide therapy for acromegaly, long term outcome — Mercado M et al., JCEM, 2014
- Sandostatin LAR Depot (octreotide acetate) - FDA Label — FDA / DailyMed (Novartis Pharmaceuticals)
- Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system — Nunes VS et al., Pituitary, 2015
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Octreotide (Sandostatin)
Full Octreotide (Sandostatin) breakdownOctreotide (Sandostatin) what it's used forOctreotide (Sandostatin) side effectsOctreotide (Sandostatin) how to take itOctreotide (Sandostatin) who should avoid itOctreotide (Sandostatin) half-lifeOctreotide (Sandostatin) how long to workOctreotide (Sandostatin) legal statusOctreotide (Sandostatin) how it worksAsk the AI Coach
Last updated 2026-06-15.